In 2025, Counterpart Health recorded a greater than 450% year-over-year increase in live third-party customer clinicians, expanding its AI-powered physician-enablement platform to hundreds of providers across multiple states. The company published three new retrospective analyses demonstrating statistically significant improvements in chronic disease management, reinforcing its position as a leader in value-based care delivery and driving broader recognition among payers and provider organizations.

Data released for the year show that returning Clover Health members whose primary care physicians use Counterpart Assistant achieved an approximately 1,500 basis-point differential in medical cost ratio compared with those whose physicians do not. The platform supported the number-one HEDIS score nationally for a PPO Medicare Advantage plan for the second consecutive year, despite a network of non-employed physicians, highlighting its ability to improve preventive care, reduce avoidable events and sustain high quality standards at scale.

Real-world analyses revealed that under Counterpart Assistant–enabled care, new members were 75% more likely to receive a diagnosis of COPD in their first year, and COPD patients experienced an average 18% increase in outpatient pulmonology visits, indicating better specialty coordination. Additionally, all-cause hospitalizations for congestive heart failure were 18% lower and for COPD 15% lower, with 30-day readmissions decreasing by 25% for heart failure and 18% for COPD. In high Area Deprivation Index neighborhoods, diagnosis rates for four major chronic conditions were 70–89% higher when PCPs leveraged the platform’s insights.

Among five analysts covering Clover Health, one has issued a sell recommendation, three have rated the stock as hold and one has maintained a buy recommendation, resulting in a consensus “Hold” rating. Institutional investors have adjusted positions across the past two quarters, with notable increases including a 21.7% boost by Janney Montgomery Scott LLC and a 53.5% gain by Swiss Life Asset Management Ltd, while hedge funds collectively account for nearly 20% of outstanding shares, reflecting continued investor interest in the company’s technology-driven growth strategy.